Condensed Consolidated Statements of Cash Flows (Unaudited) - USD ($) $ in Millions	1 Months Ended	5 Months Ended	6 Months Ended
	Jun. 30, 2023	May 17, 2023	Jun. 30, 2024
Operating Activities
Net Income (Loss)	$ 31	$ 465	$ 777
Non-cash reconciliation adjustments:
Unrealized (gains) losses on derivative instruments	(39)	65	36
(Gain) loss on Cumulus Data Campus Sale and ERCOT Sale	0	0	(886)
(Gain) loss on sales of assets, net	0	(50)	0
Nuclear fuel amortization	25	33	63
Depreciation, amortization and accretion	27	208	144
Impairments	0	381	0
NDT funds (gain) loss, net (excluding interest and fees)	(33)	(43)	(80)
Deferred income taxes	16	195	94
Reorganization (income) expense, net	0	(933)	0
Other	17	7	(58)
Changes in assets and liabilities:
Accounts receivable, net	(5)	261	(14)
Inventory, net	(11)	10	90
Other assets	22	98	34
Accounts payable and accrued liabilities	(89)	(69)	(114)
Accrued interest	25	(124)	(1)
Other liabilities	13	(42)	65
Net cash provided by (used in) operating activities	(1)	462	150
Investing Activities
Property, plant and equipment expenditures	(20)	(138)	(45)
Nuclear fuel expenditures	(14)	(49)	(44)
NDT funds investment sale proceeds	273	949	1,095
NDT funds investment purchases	(279)	(959)	(1,110)
Equity investments in affiliates	0	(8)	(5)
Proceeds from Cumulus Data Campus Sale and ERCOT Sale (Note 17)	0	0	1,089
Proceeds from the sale of assets	0	46	1
Other investing activities	2	2	(2)
Net cash provided by (used in) investing activities	(38)	(157)	979
Financing Activities
Contributions from member	0	1,393	0
Financing proceeds at Emergence, net of discount	0	2,219	0
Repayment of Prepetition Secured Indebtedness	0	(3,898)	0
Payment of make-whole premiums on Prepetition Secured Indebtedness	0	(152)	0
LMBE-MC TLB payments	(1)	(7)	0
Cumulus Digital TLF repayment	0	0	(182)
Share repurchases (Note 15)	0	0	(654)
Repurchase of noncontrolling interest	0	0	(39)
Cash settlement of restricted stock units	0	0	(28)
Deferred finance costs	0	(74)	0
Derivatives with financing elements	0	(20)	0
Other	1	0	(12)
Net cash provided by (used in) financing activities	0	(539)	(915)
Net Increase (Decrease) in Cash and Cash Equivalents and Restricted Cash and Cash Equivalents	(39)	(234)	214
Beginning of period cash and cash equivalents and restricted cash and cash equivalents	754	988	901
End of period cash and cash equivalents and restricted cash and cash equivalents	$ 715	$ 754	$ 1,115